HPV ctDNA as a Biomarker for Monitoring Disease Progression in HPV16/18-Associated Cervical Cancer
Pathobiology · 2025
DOI: 10.1159/000548452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, 2025. Verfasst von Meejeong Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Human papillomavirus 16, Human papillomavirus 18, Circulating Tumor DNA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Cervical cancer, primarily driven by oncogenic HPV16/18, often relapses despite standard treatments. HPV circulating tumor DNA (ctDNA), which reflects tumor-derived genetic material in the bloodstream, has emerged as a promising noninvasive biomarker for monitoring disease progression.
Methods
A prospective study was conducted on 20 patients with HPV16/18-associated cervical cancer. Posttreatment blood samples were collected, and HPV ctDNA levels were measured using droplet digital PCR. The correlation between HPV ctDNA levels and disease progression was examined.
Results
HPV ctDNA was detected in 21% (18/85) of samples, with 6% (5/85) showing positivity. Patients without disease progression (n = 15) were HPV ctDNA negative, indicating a false positivity rate of zero. HPV ctDNA concentrations appeared higher in samples collected before or during disease progression, suggesting a potential association with disease status. Patients with positive HPV ctDNA tended to have shorter progression-free survival compared to those with negative ctDNA.
Conclusions
This study suggests that HPV ctDNA may aid in monitoring disease progression in patients with HPV16/18-associated cervical cancer, highlighting the need for further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, hohoho@catholic.ac.kr.
- Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, klee@catholic.ac.kr.
- Cancer Research Institute, The Catholic University of Korea, Seoul, Republic of Korea, klee@catholic.ac.kr.
Zitieren
APA
Kim, M., Lee, M., Kang, J., Lee, S. J., Hong, S. H., Lee, K. H., & Lee, A. (2025). HPV ctDNA as a Biomarker for Monitoring Disease Progression in HPV16/18-Associated Cervical Cancer. Pathobiology. https://doi.org/10.1159/000548452
Vancouver
Kim M, Lee M, Kang J, Lee SJ, Hong SH, Lee KH, et al. HPV ctDNA as a Biomarker for Monitoring Disease Progression in HPV16/18-Associated Cervical Cancer. Pathobiology. 2025. doi:10.1159/000548452
BibTeX
@article{Kim2025,
author = {Kim, Meejeong and Lee, Miseon and Kang, Jun and Lee, Sung Jong and Hong, Sook Hee and Lee, Keun Ho and Lee, Ahwon},
title = {HPV ctDNA as a Biomarker for Monitoring Disease Progression in HPV16/18-Associated Cervical Cancer},
journal = {Pathobiology},
year = {2025},
doi = {10.1159/000548452}
}
EUVIMED